Abstract:
PURPOSE: A data mining method for food safety responding to climate change is provided to search data required for safe food management by reflecting climate change factors, thereby accurately managing food in responding to climate change. CONSTITUTION: A region for data mining, the climate factor of the region, and the temporal range of the climate factor are selected (S100). A hazard factor to be used for data mining is selected among hazard factors caused by harmful materials (S110). A search is performed in a database, which has monitoring data and the climate factor data, in connection with the region, climate factor, temporal range, and hazard factor (S120). A linked search calculates the amount of a change in the climate factor in the temporal range and searches the database based on the change. [Reference numerals] (S100) Region for data mining, the climate factor of the region, and the temporal range of the climate factor are selected; (S110) Hazard factor to be used for data mining is selected among hazard factors caused by harmful materials; (S120) Search is performed in a database, which has monitoring data and the climate factor data, in connection with the region, climate factor, temporal range, and hazard factor
Abstract:
PURPOSE: A method for identifying the mixture of meat ingredients in a food ingredient is provided to enable scientific food monitoring and to block distribution of bad foods. CONSTITUTION: A method for identifying the mixture of meat ingredients in a food ingredient comprises: a step of extracting DNA from the food ingredient; a step of performing PCR comprising first, second, third, fourth, fifth, and sixth steps using the DNA and a primer set; and a step of detecting the presence of meats including bos taurus, sus scrofa, ovis aries, capra hircus, cervus elaphus, cervus Nippon, and equus caballus.
Abstract:
본 발명은 유방암 관련 Her2 (ERBB2) 수용체에 특이적으로 결합하는 DNA 압타머, 이를 유효성분으로 함유하는 암전이 억제용 조성물 및 암진단용 조성물에 관한 것으로, 상기 압타머는 기존의 항체와는 다른 결합 기작을 가짐으로써 보다 효과적으로 암 전이를 억제하고 암을 진단할 수 있는 것을 특징으로 한다.
Abstract:
PURPOSE: An inspection device and a method for medical application authentication are provided to simply and accurately perform authentication. CONSTITUTION: An inspection system(200) includes a reception unit(210), analysis unit(220), a transmission unit(230), an output unit(240) and an authentication unit(250). The reception unit receives measurement information from a medical device. The analysis unit analyzes the received measurement information for judging matching between the received measurement information and a pre-defined standard technology. The analysis unit parses an inspection target in the measurement information, converting the parsed information into a byte value and compares the byte value with a defined value in the standard technology. The transmission unit transmits the received measurement information to the medical application in case the analyzed result from the analysis unit is matched with the standard technology. The authentication unit identifies individual, medical personnel or medical treatment center. [Reference numerals] (210) Reception unit; (220) Analysis unit; (230) Transmission unit; (240) Output unit; (250) Authentication unit
Abstract:
PURPOSE: A transgenic animal which expresses human GATA3 gene under the regulation of a cytomegalovirus promoter is provided to study the function of GATA3 protein in vivo and correlation between GATA3 protein and allergic disease. CONSTITUTION: A transgenic fertilized egg(deposit number KCTC 12001BP) is prepared by transforming human GATA3 gene of sequence number 1. A transgenic mouse is produced by the fertilized egg. An expression cassette has human GATA3 gene which is linked with a cytomegalovirus promoter. A method for preparing a pCMV/hGATA3 expression cassette comprises: a step of amplifying a human GATA3 base sequence by PCR; and a step of cloning to pcDNA3.1 V5-His-TOPO vector.
Abstract:
PURPOSE: A method for discriminating nephrotoxicity of a drug and a method for screening a nephrotoxicity-inducing material are provided to accurately determine nephrotoxicity with high sensitivity and specificity. CONSTITUTION: A method for determining nephrotoxicity of a drug comprises: a step of measuring concentration 1 of acetate and dimethyl glycine contained in urine from a drug-injected individual; a step of comparing concentration 1 with concentration 2 of acetate and dimethyl glycine contained in urine from a control group; and a step of determining whether concentration 1 is significantly changed. A method for screening a nephrotoxicity-inducing material comprises: a step of injecting a test composition or a test compound into an individual as an experimental group; a step of measuring and comparing the concentration of acetate and dimethyl glycine contained in urine from a control group; and a step of selecting a test composition or test compound which significantly changes the concentration of acetate and dimethyl glycine compared with the control group.
Abstract:
본 발명은 사람의 B형 간염바이러스 X유전자로 형질전환된 동종접합 마우스에 목적하는 약물을 투여하고, 시험약물을 투여하지 않은 마우스와 비교하여 시험약물의 발암성 여부를 확인하는 단계를 포함하는 발암성을 나타내는 약물을 판별하는 방법에 관한 것이다. 본 발명의 발암성을 나타내는 약물을 판별하는 방법은 (i) 사람의 B형 간염 바이러스 X 유전자로 형질전환된 동형접합(homozygous) HBx Ob 마우스(KCTC 11068BP)에 시험약물을 투여하고 사육하는 단계; 및, (ii) 상기 마우스로부터 간을 적출하여, 적출된 간 조직의 병변을 관찰한 다음, 시험약물을 투여하지 않은 HBx Ob 마우스의 그것들과 비교하여, 시험약물의 발암성 여부를 확인하는 단계를 포함한다. 본 발명의 방법을 이용하면, 목적하는 약물의 간 발암성을 단시간에 효과적으로 예측하여, 신약의 발암성 시험에 소요되는 비용과 시간을 절감할 수 있으므로, 보다 경제적이고 효과적인 의약의 개발에 널리 이바지 할 수 있을 것이다. B형 간염 바이러스 X 유전자, 시험약물, 발암성
Abstract:
PURPOSE: An analysis kit for haplotypes of a UGT1A1 gene promoter is provided to predict the expression level of the UGT1A1 gene and to develop drugs. CONSTITUTION: A method for analyzing haplotypes of the human UGT1A1 gene comprises: a step of performing PCR using a human UGT1A1 gene promoter or fragment thereof; a step of analyzing the base sequence of a DNA product; and a step of determining the presence of an SNP of -1352 A>C(3676th base of sequence number 8) and -997 G>A(4031th base of sequence number 8).
Abstract:
본 발명은 CYP3A5를 암호화하는 유전자의 단일염기 다형성(single nucleotide polymorphism, SNP)의 위치 및 유전적 변이를 확인하고, 이를 분석지표로 사용되는 상기 유전자의 일배체형에 적용하여 분석하는 단계를 포함하는, 상기 유전자의 유전적 다형성을 분석하는 방법에 관한 것이다. 본 발명의 CYP3A5를 암호화하는 유전자의 유전적 다형성을 분석하는 방법은 (ⅰ) 게놈 DNA로부터 CYP3A5를 암호화하는 유전자의 인트론 1, 인트론 3, 인트론 4, 인트론 9, 엑손 13 및 단백질로 번역되지 않은 3' 부위를 수득하고, 이들 각각의 염기서열을 결정하는 단계; (ⅱ) 상기 결정된 각 염기서열에서 단일염기 다형성(SNP)의 존재여부를 검출하는 단계; 및, (ⅲ) 상기 검출된 SNP를 H1 내지 H7에서 선택되는 일배체형으로 동정하고, 상기 동정된 일배체형을 이용하여 상기 유전자의 유전적 다형성을 분석하는 단계를 포함한다. 본 발명의 방법을 이용하면, 보다 용이하게 CYP3A5 유전자의 유전적 다형성을 분석할 수 있으므로, CYP3A5에 의하여 대사되는 약물의 개발에 널리 활용될 수 있을 것이다. CYP3A5, 단일염기 다형성, 일배체형
Abstract:
PURPOSE: A method for determining drug toxicity in the kidney is provided to reduce time and cost and to obtain stable data. CONSTITUTION: A method for determining drug toxicity in the kidney comprises: a step of injecting test drug to a mammal except for human; a step of collecting urine and measuring metabolite concentration; a step of comparing with the metabolite concentration of a control group; and a step of determining drug toxicity in the kidney. The metabolite relating to toxicity in the kidney is 2-oxoglutarate, acetate, lactate, allantoin, citrate, taurine, succinate, glucose, alanine, or formate.